Our ultimate goal is to develop an effective malaria vaccine by utilizing recombinant malaria antigens. The Plasmodium /alciparum SERA
(126kDa), one of the vaccine candidate antigens, is an asexual blood stage antigen produced in large amounts specifically during late trophozoite and schizonts stages (ref. 1, 2) . The primary SERA polypeptide is secreted into the lumen of the parasitophorous vacuole, then a large fraction of 126kDa SERA protein is proteolytically processed into three fragments coincident with the release of merozoites.
We expressed N -terminal domain (SE47'), central domain (SE50A) and C-terminal domain (SE18) of SERA protein in E. coli by synthesizing the genes with a changed codon usage fit for the E. coli system. Antisera against the purified gene products prepared in rats and mice were examined their inhibitory effect on malaria parasite growth in vitro (ref. 3) . The anti-SE47' serum was significantly more inhibitory than the other sera. Affinity-purified mouse IgG specific to the recombinant SE47' protein inhibited the parasite growth at the stage from schizont to ring. Immunofluorescence assay (IF A) revealed that the IgG molecules were surround the rupturing schizonts and the released merozoites cross- The current data supports the feasibility of E. coli produced SE47' protein to be an effective malaria vaccine.
